Drug treatment of multiple sclerosis

BMJ

Volumn 322, Issue 7281, 2001, Pages 299-

  Milne, Ruairidh ^a   Clegg, Andy ^a   Bryant, Jackie ^a   Polman, C H ^b   Uitdehaag, B M J ^b  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; IMMUNOSUPPRESSIVE AGENT;

COST EFFECTIVENESS ANALYSIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LETTER; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL;

DRUG COSTS; HUMANS; INTERFERON-BETA; MULTIPLE SCLEROSIS; REVIEW LITERATURE; TREATMENT OUTCOME;

EID: 0035798852     PISSN: 09598138     EISSN: 14685833     Source Type: Journal    
DOI: 10.1136/bmj.322.7281.299     Document Type: Letter

References (4)

1. Polman CH, Uitdehaag BMJ. Drug treatment of multiple sclerosis. BMJ 2000; 321: 490–494. (19-26 August.)
2. Kappos L, Moeri D, Radue EW, Schoetzau A, Schweikert K, Barkhof F, et al. Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Lancet 1999; 353: 964–969.
3. Clegg A, Bryant J, Milne R. Disease-modifying drugs for multiple sclerosis: a rapid and systematic review. Health Technol Assess 2000; 4: 1–101.
4. Bryant J, Clegg A, Milne R. Cost utility of drugs for multiple sclerosis. Systematic review places study in context. BMJ 2000; 320: 1474–1475. (27 May.)